JPMorgan analyst Anupam Rama lowered the firm’s price target on Vera Therapeutics (VERA) to $71 from $77 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target raised to $61 from $59 at Guggenheim
- Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
- Vera Therapeutics selloff a buying opportunity, says Evercore ISI
- Buy Rating for Vera Therapeutics: Atacicept’s Unique Potential in the IgAN Market
- Vera Therapeutics pullback a buying opportunity, says Cantor Fitzgerald